VIEMED HEALTHCARE, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $VMD in the last 7 days.
VMD Corp, part of Xcelerate Solutions, won a spot on the TSA's SPP IDIQ contract, valued up to $5bn. This positions the company to bid on future aviation security projects. VMD already supports screening at airports like Kansas City and San Francisco.
Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions
Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.
Recent VMD coverage spans earnings, financial news and corporate actions.
In the last 30 days, VMD insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($105K). The most active reporter was Heltz Sabrina with 1 filing.
The contract positions VMD to compete for future aviation security work, potentially boosting revenue.
Guidance suggests modest growth with expanding sleep and maternal health lines, potentially supporting the stock price.
Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.
Strong revenue growth and a new buyback program may support the stock price.
Insider sale of ~4.2K shares for $37K and large RSU vesting increase insider holdings.
AlphAI scores every news story that mentions VMD with an AI model for sentiment and relevance, and aggregates insider trades from VIEMED HEALTHCARE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
VMD Corp, part of Xcelerate Solutions, won a spot on the TSA's SPP IDIQ contract, valued up to $5bn. This positions the company to bid on future aviation security projects. VMD already supports screening at airports like Kansas City and San Francisco.
1 min readViemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions
2 min readViemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.
2 min readVieMed Healthcare reported 2025 results with $270.3M revenue, $61.4M Adjusted EBITDA, and $28.1M free cash flow. For 2026, it projects $314M–$320M revenue and $64M–$68M Adjusted EBITDA, with a new share buyback program. The company highlights growth, cash generation, and strategic initiatives.
1 min readViemed Healthcare (VMD) director Randy E. Dobbs settled 16,763 Restricted Stock Units and 4,191 Phantom Share Units, acquiring and then disposing of 4,191 common shares at $8.94 each. He also received a new grant of 16,848 RSUs, vesting in 2027. The transactions reflect insider equity award activity.
2 min readViemed Healthcare (VMD) director Sabrina Heltz exercised 15,029 RSUs and 3,757 Phantom Share Units, converting them into common shares. She also received new grants of 12,174 RSUs and 3,043 Phantom Share Units, set to vest in 2027. The Phantom Share Units were settled at $8.94 per share.
1 min readViemed Healthcare (VMD) director Timothy Smokoff exercised 15,029 RSUs and settled 3,757 Phantom Share Units, returning 3,757 common shares to the company at $8.94 per share. He also received new grants of 12,174 RSUs and 3,043 Phantom Share Units, both vesting in one year. Transactions were not under a Rule 10b5-1 plan.
1 min readViemed Healthcare (VMD) reported Q2 2026 revenue of $78.1M, up 24% year over year, with ventilator patient counts reaching 12,635. Adjusted EBITDA was $13.7M (17.6% margin) and net income was $2.8M. Full-year 2026 revenue guidance was raised to $314M-$320M and adjusted EBITDA to $64M-$68M.
6 min readViemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.
6 min readViemed Healthcare (NASDAQ:VMD) reported Q2 2026 results for the three and six months ended June 30, 2026 and updated 2026 guidance. Cash was $10.7M, working capital $6.1M, and it repaid $2.2M of a term loan. Net revenue guidance was raised at the low end; net capex is now 8.5% to 10.0% of net revenue.
4 min read
